OLD National Bancorp IN Buys Shares of 10,000 Immix Biopharma, Inc. (NASDAQ:IMMX)

OLD National Bancorp IN bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) during the 4th quarter, HoldingsChannel reports. The fund bought 10,000 shares of the company’s stock, valued at approximately $69,000.

Other hedge funds have also recently bought and sold shares of the company. Commonwealth Equity Services LLC increased its holdings in Immix Biopharma by 26.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 28,855 shares of the company’s stock valued at $99,000 after buying an additional 6,030 shares during the period. Imprint Wealth LLC grew its holdings in shares of Immix Biopharma by 49.4% during the 4th quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock valued at $239,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of Immix Biopharma during the 3rd quarter valued at approximately $41,000. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Trading Up 1.4 %

Shares of Immix Biopharma stock opened at $2.13 on Friday. The firm’s 50 day moving average is $2.91 and its 200 day moving average is $4.03. Immix Biopharma, Inc. has a 1 year low of $1.40 and a 1 year high of $7.75. The firm has a market capitalization of $56.23 million, a PE ratio of -2.39 and a beta of 0.05.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Friday, March 29th. The company reported ($0.24) EPS for the quarter. As a group, research analysts anticipate that Immix Biopharma, Inc. will post -0.91 earnings per share for the current year.

Immix Biopharma Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.